Reaction
Application Site Warmth reporting signals
As of the last recalculation, Application Site Warmth appears in 1,264 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is NICOTINE (PRR 75.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nicotine | 162 | 75.5 | 75.8 |
| Crisaborole | 17 | 29.6 | 29.6 |
| Oxybutynin | 31 | 17.8 | 17.9 |
| Miconazole Nitrate | 9 | 17.1 | 17.1 |
| Minoxidil | 38 | 14.3 | 14.3 |
| Nicotine Polacrilex | 32 | 14.1 | 14.1 |
| Glycerin, Lidocaine | 11 | 13.0 | 13.1 |
| Docosanol | 11 | 12.5 | 12.5 |
| Nicotine Polacrilex Mini | 11 | 12.2 | 12.2 |
| Nicotine Polarilex | 11 | 12.2 | 12.2 |
| Methylphenidate | 21 | 12.1 | 12.1 |
| Minoxidil Foam 5% (Womens) | 20 | 10.1 | 10.1 |
| Rotigotine | 7 | 8.0 | 8.0 |
| Granisetron | 5 | 7.9 | 7.9 |
| Buprenorphine | 40 | 7.3 | 7.3 |
| Lifitegrast | 3 | 3.0 | 3.0 |
| Pegfilgrastim | 17 | 2.9 | 2.9 |
| Salicylic Acid | 5 | 1.6 | 1.6 |